Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | ACP1 | P24666 | 2/20 | 0.30 |
| ▸ | CDC25B | P30305 | 2/20 | 0.30 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7086453 | 0.81 | NR4A2 (0.30) | — | |
| SCHEMBL23674603 | 0.80 | PTPN1 (0.33) | PTPN1ACP1CDC25B | |
| SCHEMBL1264921 | 0.78 | BACE1 (0.30) | BACE1 | |
| SCHEMBL25068529 | 0.78 | L3MBTL1 (0.31) | — | |
| SCHEMBL23674614 | 0.78 | — | — | |
| SCHEMBL7235362 | 0.78 | ALDH1A1 (0.33) | PTPN1ACP1CDC25B | |
| SCHEMBL25308664 | 0.77 | — | — | |
| SCHEMBL7088382 | 0.77 | — | — | |
| SCHEMBL7086621 | 0.76 | POLB (0.38) | — | |
| SCHEMBL10181931 | 0.76 | PTPN1 (0.43) | PTPN1ACP1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252477-B2 | Applications of known and novel cannabinoids | BESSOR PHARMA, LLC (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240101503-A1 | Process for the Production of Cannabinoids and Cannabinoid Acids | BESSOR PHARMA, LLC | 2024-03-28 | — | — | US | disclosed |
| EP-3840852-B1 | PROCESS FOR THE PRODUCTION OF CANNABINOIDS | BESSOR PHARMA LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11685724-B2 | Synthetic intermediates for novel cannabinoids and cannabinoid acids and their derivatives | BESSOR PHARMA, LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685724-B2 | Synthetic intermediates for novel cannabinoids and cannabinoid acids and their derivatives | BESSOR PHARMA, LLC (US) | 2023-06-27 | — | — | US | disclosed |
| CN-113164829-B | Use of known and novel cannabinoids | 贝索制药有限责任公司 | 2023-02-21 | — | — | CN | disclosed |
| CN-113164830-B | Process for the preparation of cannabinoids | 贝索制药有限责任公司 | 2023-02-21 | — | — | CN | disclosed |
| US-20220340537-A1 | Synthetic Intermediates for Novel Cannabinoids and Cannabinoid Acids and Their Derivatives | BESSOR PHARMA, LLC | 2022-10-27 | — | — | US | disclosed |
| EP-4041703-A1 | PROCESS FOR THE PRODUCTION OF CANNABINOIDS AND CANNABINOID ACIDS | Bessor Pharma, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| US-11407724-B2 | Process for the production of cannabinoids | BESSOR PHARMA, LLC (US) | 2022-08-09 | — | — | US | disclosed |
| US-20210236460-A1 | Applications of Known and Novel Cannabinoids | BESSOR PHARMA, LLC | 2021-08-05 | — | — | US | disclosed |
| CN-113164829-A | Use of known and novel cannabinoids | 贝索制药有限责任公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210198224-A1 | Process for the Production of Cannabinoids | BESSOR PHARMA, LLC | 2021-07-01 | — | — | US | disclosed |
| EP-3840854-A1 | NOVEL CANNABINOIDS AND CANNABINOID ACIDS AND THEIR DERIVATIVES | Bessor Pharma, LLC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3840852-A1 | PROCESS FOR THE PRODUCTION OF CANNABINOIDS | Bessor Pharma, LLC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3840853-A1 | APPLICATIONS OF KNOWN AND NOVEL CANNABINOIDS | Bessor Pharma, LLC (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2021071908-A1 | PROCESS FOR THE PRODUCTION OF CANNABINOIDS AND CANNABINOID ACIDS | BERKOWITZ BARRY A (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2020041322-A1 | NOVEL CANNABINOIDS AND CANNABINOID ACIDS AND THEIR DERIVATIVES | BERKOWITZ BARRY A (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020041326-A1 | APPLICATIONS OF KNOWN AND NOVEL CANNABINOIDS | BERKOWITZ BARRY A (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020041321-A1 | PROCESS FOR THE PRODUCTION OF CANNABINOIDS | BERKOWITZ BARRY A (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101503-A1 | Process for the Production of Cannabinoids and Cannabinoid Acids | CNR2, CNR1, RARG | PTPN1 4723/4885BACE1 1685/4885ACP1 3859/4885 |
| US-11407724-B2 | Process for the production of cannabinoids | CNR2, CNR1, DHCR24 | PTPN1 4737/4885BACE1 496/4885ACP1 3236/4885 |
| US-12252477-B2 | Applications of known and novel cannabinoids | CNR2, CNR1, FAAH | PTPN1 3537/4885BACE1 263/4885ACP1 4165/4885 |
| US-11685724-B2 | Synthetic intermediates for novel cannabinoids and cannabinoid acids and their derivatives | CNR2, CNR1, GPR18 | PTPN1 4648/4885BACE1 1295/4885ACP1 2535/4885 |
| US-20210236460-A1 | Applications of Known and Novel Cannabinoids | CNR2, CNR1, FAAH | PTPN1 3537/4885BACE1 263/4885ACP1 4165/4885 |
| US-20210198224-A1 | Process for the Production of Cannabinoids | CNR2, CNR1, DHCR24 | PTPN1 4737/4885BACE1 496/4885ACP1 3236/4885 |
| US-20220340537-A1 | Synthetic Intermediates for Novel Cannabinoids and Cannabinoid Acids and Their Derivatives | CNR2, CNR1, GPR18 | PTPN1 4648/4885BACE1 1295/4885ACP1 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.